Product Information:

ZURIG 80mg Tablets contain Febuxostat 80mg, a selective xanthine oxidase inhibitor used for the chronic management of hyperuricemia in adults with gout. Febuxostat reduces serum uric acid levels by inhibiting xanthine oxidase, the enzyme responsible for uric acid production. The 80mg dose is the maximum recommended strength, typically used when the 40mg dose fails to achieve target serum uric acid levels (<6 mg/dL).

Uses of (ZURIG 80MG TABLETS):

1. Chronic gout with persistent hyperuricemia despite 40mg febuxostat
2. Patients intolerant or unresponsive to allopurinol
3. Prevention of recurrent gout flares and tophi formation

Key Benefits of (ZURIG 80MG TABLETS):

1. Once-daily dosing for sustained uric acid control
2. No dose adjustment needed in mild-to-moderate renal impairment
3. Effective in achieving target serum uric acid (<6 mg/dL) in most patients
4. Alternative for allopurinol-intolerant patients

How To Use (ZURIG 80MG TABLETS):

1. Take once daily, with or without food, at the same time each day.
2. Swallow whole with water—do not crush or chew.
3. Do not initiate during an acute gout attack—start only after resolution.
4. Gout flare prophylaxis (e.g., colchicine 0.5mg once or twice daily) is recommended for the first 6 months to prevent flares triggered by uric acid mobilization.

When Not to Use (ZURIG 80MG TABLETS):

Do not use if you have:

1. Hypersensitivity to febuxostat
2. Concurrent use of azathioprine or mercaptopurine (risk of life-threatening toxicity)
3. Asymptomatic hyperuricemia (not indicated without gout history)
4. Severe hepatic impairment (use with extreme caution)

⚠️ Black Box Warning (FDA):

Febuxostat may increase the risk of cardiovascular death compared to allopurinol, especially in patients with pre-existing heart disease. Reserve for patients who cannot tolerate allopurinol after careful risk-benefit assessment.

Side Effects of (ZURIG 80MG TABLETS):

Common:

1. Liver enzyme elevation (ALT/AST)
2. Nausea, diarrhea
3. Gout flare (early in treatment)
4. Arthralgia, rash

Less common:

1. Headache, dizziness
2. Edema

Serious (rare but require monitoring):

1. Hepatotoxicity (jaundice, dark urine, fatigue)—monitor LFTs periodically
2. Severe cutaneous reactions (e.g., Stevens-Johnson syndrome)
3. Cardiovascular events (myocardial infarction, stroke, arrhythmia)—especially in high-risk patients
4. Discontinue and seek emergency care if signs of liver injury or cardiac symptoms occur.

Dosage: (ZURIG 80MG TABLETS):

1. Maintenance dose: 80mg once daily
2. Only escalate from 40mg if serum uric acid remains ≥6 mg/dL after ≥2 weeks
3. Maximum dose: 80mg/day
4. Renal impairment: No adjustment needed for CrCl ≥30 mL/min

Who It’s For (ZURIG 80MG TABLETS):

Adults with chronic gout uncontrolled on febuxostat 40mg, particularly those with significant tophi, frequent flares, or intolerance to allopurinol—and who have no major cardiovascular risk factors.

Warnings & Precautions:

1. Monitor liver function tests (LFTs) before starting and periodically thereafter
2. Evaluate cardiovascular risk thoroughly before initiation
3. Avoid in patients with active liver disease
4. Provide gout flare prophylaxis for first 6 months of therapy

Drug Interactions:

1. Azathioprine / Mercaptopurine: Contraindicated—febuxostat inhibits their metabolism → severe myelosuppression
2. Theophylline: May increase levels—monitor for nausea, tachycardia, seizures
3. Always inform your doctor about all medications.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date. Available by prescription in Pakistan.